Edition:
India

People: Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

3.91USD
17 Jun 2019
Change (% chg)

-- (--)
Prev Close
$3.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,099,985
52-wk High
$18.50
52-wk Low
$3.84

Campanelli, Paul 

Mr. Paul V. Campanelli serve as President, Chief Executive Officer, Director of the Company. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industry-leading generics business. Under his leadership, the company significantly increased total revenue, acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He also served on the board of directors of Sky Growth Holdings Corporation. Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd. where he was employed from 1992-2001. Mr. Campanelli earned his Bachelor of Science degree from Springfield College.

Basic Compensation

Total Annual Compensation, USD 1,699,540
Restricted Stock Award, USD 2,179,570
Long-Term Incentive Plans, USD --
All Other, USD 4,613,800
Fiscal Year Total, USD 8,492,910

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --